Enanta Pharmaceuticals has filed a patent infringement action in the Unified Patent Court $(UPC)$ of the European Union against Pfizer Inc. and certain subsidiaries. The lawsuit concerns alleged infringement of European Patent No. EP 4 051 265 related to the manufacture, use, and sale of Paxlovid™ (nirmatrelvir tablets; ritonavir tablets) in 18 EU member states participating in the UPC. A hearing on the action is expected within the UPC's 12-month target timeline, with a decision anticipated shortly thereafter. An update on the litigation is expected in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260108666055) on January 08, 2026, and is solely responsible for the information contained therein.